Scandion Oncology
«Our goal at Scandion Oncology is to develop drugs that specifically target chemotherapy resistance mechanisms. Improving the outcome and quality of life for cancer patients is our mission.
Drug resistance is one of the most significant challenges for successful medical treatment in oncology. Right now, half of all cancer patients fail chemotherapy.
Although many cancer patients initially benefit from chemotherapy, a large proportion develop resistance against chemotherapy drugs. Few of these patients survive.»
Scandion er et selskap som har gått fra kurs: 9,9kr (mars iår) til 50,6kr (idag). Skrev for første gang om Scandion inne på en annen tråd for 1 uke siden (daværende kurs:40kr).
Dette er et selskap som har vært under radaren lenge. Deres eneste konkurrent ORIC er verdsatt Til kr 6,4milliarder (Scandion 970millioner SEK). ORIC er kun i fase 1 på sine prøver, mens Scandion legger frem sine fase 2 prøver imorgen tidlig!
Det er allerede spekulasjoner og rykter om at «BIG-pharma» selskap ønsker å kjøpe Scandion, hvilket vil dra kursen til EKSTREME høyder.
Er veldig trygg på at aksjen vil ligge et sted mellom 100-150kr ila august måned, og at den får en SOLID oppgang etter at prøveresultatene legges frem imorgen. Tipper 20% oppgang imorgen
Drug resistance is one of the most significant challenges for successful medical treatment in oncology. Right now, half of all cancer patients fail chemotherapy.
Although many cancer patients initially benefit from chemotherapy, a large proportion develop resistance against chemotherapy drugs. Few of these patients survive.»
Scandion er et selskap som har gått fra kurs: 9,9kr (mars iår) til 50,6kr (idag). Skrev for første gang om Scandion inne på en annen tråd for 1 uke siden (daværende kurs:40kr).
Dette er et selskap som har vært under radaren lenge. Deres eneste konkurrent ORIC er verdsatt Til kr 6,4milliarder (Scandion 970millioner SEK). ORIC er kun i fase 1 på sine prøver, mens Scandion legger frem sine fase 2 prøver imorgen tidlig!
Det er allerede spekulasjoner og rykter om at «BIG-pharma» selskap ønsker å kjøpe Scandion, hvilket vil dra kursen til EKSTREME høyder.
Er veldig trygg på at aksjen vil ligge et sted mellom 100-150kr ila august måned, og at den får en SOLID oppgang etter at prøveresultatene legges frem imorgen. Tipper 20% oppgang imorgen
Redigert 20.01.2021 kl 20:58
Du må logge inn for å svare
Gamebred
31.07.2020 kl 10:10
1250
«Scandion Oncology A/S (“Scandion Oncology”) reports on data from the first cohort of chemotherapy resistant colorectal cancer patients treated with SCO-101 and chemotherapy (FOLFIRI). All patients in the first cohort have now completed at least one treatment cycle (14 days). The main result is that 150 mg daily oral SCO-101 potentiates the effects of chemotherapy (FOLFIRI). Based on the safety data from this first cohort of patients, the Data Safety Monitoring Board has recommended to include 3 additional patients at 150 mg SCO-101 in order to get more details on the interactions between SCO-101 and FOLFIRI.
The patients included are patients with late stage metastatic colorectal cancer, for whom no additional treatment is available. All patients have previously had benefit with FOLFIRI (chemotherapy) treatment but subsequently, their cancer started to grow or the patient showed new metastatic lesions and they were offered to be enrolled in the Scandion Oncology clinical phase II trial. The primary objective of the trial is to establish the safety, tolerability and Maximum Tolerated Dose of SCO-101 in combination with FOLFIRI chemotherapy, and by the addition of SCO-101 to re-establish treatment benefits of FOLFIRI.
Data from the first patients treated in cohort 1 showed, (i) SCO-101 at a daily oral dose of 150 mg for 6 days results in the expected transient increase of the exposure biomarker bilirubin. This transient increase in bilirubin is of no clinical significance; (ii) SCO-101 potentiated the effects of FOLFIRI on white blood cells; (iii) SCO-101 dosed in combination with FOLFIRI decreases blood concentrations of the liver enzymes ASAT and ALAT. ASAT and ALAT are enzymes released from damaged liver cells; (iiii) All patients are assessed at 8 week intervals by a CT-scan for status on their disease. Due to the early stage of the trial, only one patient has currently completed 8 weeks treatment. This first patient showed stabilization of his cancer disease and has therefore continued treatment. Additional PRs regarding the efficacy end-points will be published at a later time point when we have more data.
CEO Nils Brünner says “"The possibility to reverse chemotherapy resistance is groundbreaking, giving countless patients worldwide a new chance in life; Scandion Oncology is therefore very pleased to present the results of our first patients treated with SCO-101 in combination with chemotherapy. The most important observation at this early stage is that an oral dose of 150 mg SCO-101 combined with chemotherapy appears to be biological active as measured by potentiating a decrease in white blood cells, in transiently increasing the blood level of bilirubin, reducing the blood level of liver enzymes and by inducing stable cancer disease in the first patient. That 150 mg SCO-101 is biologically active in cancer patients is in line with our many preclinical data. As soon as we have reached the recommended dose of SCO-101 for phase II when given together with chemotherapy, we will start the second part of the phase II study where treatment efficacy is the primary end-point”.
A more detailed description of the results will be available for potential partners.
For further information regarding Scandion Oncology, please contact:
Nils Brünner, CEO
The patients included are patients with late stage metastatic colorectal cancer, for whom no additional treatment is available. All patients have previously had benefit with FOLFIRI (chemotherapy) treatment but subsequently, their cancer started to grow or the patient showed new metastatic lesions and they were offered to be enrolled in the Scandion Oncology clinical phase II trial. The primary objective of the trial is to establish the safety, tolerability and Maximum Tolerated Dose of SCO-101 in combination with FOLFIRI chemotherapy, and by the addition of SCO-101 to re-establish treatment benefits of FOLFIRI.
Data from the first patients treated in cohort 1 showed, (i) SCO-101 at a daily oral dose of 150 mg for 6 days results in the expected transient increase of the exposure biomarker bilirubin. This transient increase in bilirubin is of no clinical significance; (ii) SCO-101 potentiated the effects of FOLFIRI on white blood cells; (iii) SCO-101 dosed in combination with FOLFIRI decreases blood concentrations of the liver enzymes ASAT and ALAT. ASAT and ALAT are enzymes released from damaged liver cells; (iiii) All patients are assessed at 8 week intervals by a CT-scan for status on their disease. Due to the early stage of the trial, only one patient has currently completed 8 weeks treatment. This first patient showed stabilization of his cancer disease and has therefore continued treatment. Additional PRs regarding the efficacy end-points will be published at a later time point when we have more data.
CEO Nils Brünner says “"The possibility to reverse chemotherapy resistance is groundbreaking, giving countless patients worldwide a new chance in life; Scandion Oncology is therefore very pleased to present the results of our first patients treated with SCO-101 in combination with chemotherapy. The most important observation at this early stage is that an oral dose of 150 mg SCO-101 combined with chemotherapy appears to be biological active as measured by potentiating a decrease in white blood cells, in transiently increasing the blood level of bilirubin, reducing the blood level of liver enzymes and by inducing stable cancer disease in the first patient. That 150 mg SCO-101 is biologically active in cancer patients is in line with our many preclinical data. As soon as we have reached the recommended dose of SCO-101 for phase II when given together with chemotherapy, we will start the second part of the phase II study where treatment efficacy is the primary end-point”.
A more detailed description of the results will be available for potential partners.
For further information regarding Scandion Oncology, please contact:
Nils Brünner, CEO
Redigert 20.01.2021 kl 20:58
Du må logge inn for å svare
Gamebred
07.08.2020 kl 17:52
1119
Resultatene på første pasient var svært positive. For at man skal få POC (Proof of concept) så behøves det kun 2 pasienter med positive resultater. CEO Nils Brunner på livestream fredag forrige uke:
Q: You once claimed that Scandion Oncology would be bought by BP (Big Pharma) as soon as SCO-101 achieves POC. Sounds like that became much more realistic with the latest results. Do you still stand behind that claim?
Nils A: I certainly do. This is the agreement with several of the BP companies we have talked to.
As soon as we have the first phase II data, we share it with them and take the next step in the negotiations."
Saniona som eide en god del aksjer i Scandion har nå endelig solgt seg ut (de måtte selge for å finansiere egne prosjekter) og kursen fremover vil bare stige, opp 14,19% idag. Og opp 51% siste 3 ukene siden jeg først meldte om denne aksjen. Kurs ved stenging idag er 66,20kr.
Når Scandion får godkjent POC så vil et oppkjøp sannsynligvis ligge på et sted mellom 1mrd$-2mrd$. Hvilket vil få kursen til å mer enn 10-doble seg.
Er det så mange rike her som har råd til å overse denne aksjen?
God helg!
Q: You once claimed that Scandion Oncology would be bought by BP (Big Pharma) as soon as SCO-101 achieves POC. Sounds like that became much more realistic with the latest results. Do you still stand behind that claim?
Nils A: I certainly do. This is the agreement with several of the BP companies we have talked to.
As soon as we have the first phase II data, we share it with them and take the next step in the negotiations."
Saniona som eide en god del aksjer i Scandion har nå endelig solgt seg ut (de måtte selge for å finansiere egne prosjekter) og kursen fremover vil bare stige, opp 14,19% idag. Og opp 51% siste 3 ukene siden jeg først meldte om denne aksjen. Kurs ved stenging idag er 66,20kr.
Når Scandion får godkjent POC så vil et oppkjøp sannsynligvis ligge på et sted mellom 1mrd$-2mrd$. Hvilket vil få kursen til å mer enn 10-doble seg.
Er det så mange rike her som har råd til å overse denne aksjen?
God helg!
Redigert 20.01.2021 kl 20:58
Du må logge inn for å svare